NEOS - ネオス・ファ―マシュ―ティカルズ (Neos Therapeutics Inc.)

NEOSのニュース

   Neos Therapeutics to Present at H.C. Wainwright Virtual BioConnect Conference  2021/01/04 21:01:00 GlobeNewswire
DALLAS and FORT WORTH, Texas, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company…
   SHAREHOLDER ALERT: WeissLaw LLP Investigates Neos Therapeutics, Inc.  2020/12/10 21:52:00 PR Newswire
NEW YORK, Dec. 10, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Neos Therapeutics, Inc. ("NEOS" or the "Company") (NASDAQ: NEOS) in connection with the proposed acquisition of the Company by…
   Thinking about buying stock in Neos Therapeutics, Oncternal Therapeutics, Heat Biologics, FuelCell Energy, or Cinedigm Corp?  2020/12/10 15:50:00 PR Newswire
NEW YORK, Dec. 10, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NEOS, ONCT, HTBX, FCEL, and CIDM. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Neos Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Neos Therapeutics, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – NEOS  2020/12/10 15:31:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Neos Therapeutics, Inc. (NASDAQ: NEOS) to Aytu BioScience, Inc. is fair to Neos shareholders. Upon the effectiveness of the merger, Neos stockholders are expected to receive 0.1088 shares of Aytu common stock for each share of Neos common stock held. Halper Sadeh encourages Neos shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh
   Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue(1) Specialty Pharmaceutical Company - Stocks News Feed  2020/12/10 11:38:34 Stocks News Feed
Merger accelerates transformation to profitability, with estimated annualized cost synergies of $15M beginning FY 2022 Aytu adds Neos’ established, multi-brand ADHD portfolio, enhancing Aytu’s footprint in pediatrics and expanding its presence in adjacent specialty care segments Opportunity to leverage and further enhance Neos RxConnect, a best-in-class patient support program, for Aytu’s product portfolio of best-in-class… Read More »Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue(1) Specialty Pharmaceutical Company
   SHAREHOLDER ALERT: WeissLaw LLP Investigates Neos Therapeutics, Inc.  2020/12/10 21:52:00 PR Newswire
NEW YORK, Dec. 10, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Neos Therapeutics, Inc. ("NEOS" or the "Company") (NASDAQ: NEOS) in connection with the proposed acquisition of the Company by…
   Thinking about buying stock in Neos Therapeutics, Oncternal Therapeutics, Heat Biologics, FuelCell Energy, or Cinedigm Corp?  2020/12/10 15:50:00 PR Newswire
NEW YORK, Dec. 10, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NEOS, ONCT, HTBX, FCEL, and CIDM. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Neos Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Neos Therapeutics, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – NEOS  2020/12/10 15:31:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Neos Therapeutics, Inc. (NASDAQ: NEOS) to Aytu BioScience, Inc. is fair to Neos shareholders. Upon the effectiveness of the merger, Neos stockholders are expected to receive 0.1088 shares of Aytu common stock for each share of Neos common stock held. Halper Sadeh encourages Neos shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh
   Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue(1) Specialty Pharmaceutical Company - Stocks News Feed  2020/12/10 11:38:34 Stocks News Feed
Merger accelerates transformation to profitability, with estimated annualized cost synergies of $15M beginning FY 2022 Aytu adds Neos’ established, multi-brand ADHD portfolio, enhancing Aytu’s footprint in pediatrics and expanding its presence in adjacent specialty care segments Opportunity to leverage and further enhance Neos RxConnect, a best-in-class patient support program, for Aytu’s product portfolio of best-in-class… Read More »Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue(1) Specialty Pharmaceutical Company
   Neos Therapeutics to Host Third Quarter 2020 Financial and Operating Results Conference Call on November 9th, 2020  2020/11/02 13:00:00 GlobeNewswire
DALLAS and FORT WORTH, Texas, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company…
   SHAREHOLDER ALERT: WeissLaw LLP Investigates Neos Therapeutics, Inc.  2020/12/10 21:52:00 PR Newswire
NEW YORK, Dec. 10, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Neos Therapeutics, Inc. ("NEOS" or the "Company") (NASDAQ: NEOS) in connection with the proposed acquisition of the Company by…
   Thinking about buying stock in Neos Therapeutics, Oncternal Therapeutics, Heat Biologics, FuelCell Energy, or Cinedigm Corp?  2020/12/10 15:50:00 PR Newswire
NEW YORK, Dec. 10, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NEOS, ONCT, HTBX, FCEL, and CIDM. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Neos Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Neos Therapeutics, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – NEOS  2020/12/10 15:31:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Neos Therapeutics, Inc. (NASDAQ: NEOS) to Aytu BioScience, Inc. is fair to Neos shareholders. Upon the effectiveness of the merger, Neos stockholders are expected to receive 0.1088 shares of Aytu common stock for each share of Neos common stock held. Halper Sadeh encourages Neos shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh
   Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue(1) Specialty Pharmaceutical Company - Stocks News Feed  2020/12/10 11:38:34 Stocks News Feed
Merger accelerates transformation to profitability, with estimated annualized cost synergies of $15M beginning FY 2022 Aytu adds Neos’ established, multi-brand ADHD portfolio, enhancing Aytu’s footprint in pediatrics and expanding its presence in adjacent specialty care segments Opportunity to leverage and further enhance Neos RxConnect, a best-in-class patient support program, for Aytu’s product portfolio of best-in-class… Read More »Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue(1) Specialty Pharmaceutical Company
   Neos Therapeutics to Host Third Quarter 2020 Financial and Operating Results Conference Call on November 9th, 2020  2020/11/02 13:00:00 GlobeNewswire
DALLAS and FORT WORTH, Texas, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company…

calendar